Cetera Investment Advisers’s Cytokinetics CYTK Stock Holding History

Cetera Investment Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$570K	Sell	8,649 -5,620	-39%	-$357K	﹤0.01%	3383
2025 Q4	$907K	Sell	14,269 -2,870	-17%	-$179K	﹤0.01%	2902
2025 Q3	$942K	Buy	17,139 +10,504	+158%	+$433K	﹤0.01%	2822
2025 Q2	$219K	Buy	6,635 +731	+12%	+$25.4K	﹤0.01%	3657
2025 Q1	$237K	Buy	5,904 +1,353	+30%	+$62.2K	﹤0.01%	3468
2024 Q4	$214K	Sell	4,551 -21,484	-83%	-$1.12M	﹤0.01%	3382
2024 Q3	$1.37M	Sell	26,035 -1,285	-5%	-$71.6K	﹤0.01%	1879
2024 Q2	$1.48M	Buy	27,320 +15,366	+129%	+$928K	﹤0.01%	1801
2024 Q1	$838K	Buy	+11,954	New	+$925K	﹤0.01%	2219

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cetera Investment Advisers's CYTK Position: Q1 2026 in Review

Cetera Investment Advisers reduced its Cytokinetics (CYTK) stake by 39% in Q1 2026, selling an estimated $357K and leaving 8,649 shares worth $570K. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

Cetera Investment Advisers first reported a position in CYTK in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.48M in Q2 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Cetera Investment Advisers held 8,649 shares of Cytokinetics worth $570K as of Q1 2026.
Cetera Investment Advisers sold 5,620 Cytokinetics shares in Q1 2026, an estimated $357K.
Cytokinetics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #3383 holding.
Cetera Investment Advisers first reported a position in Cytokinetics in Q1 2024 and has held it in 9 quarters since.
Cetera Investment Advisers's Cytokinetics position peaked at $1.48M in Q2 2024.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.